Citi Sticks to Their Hold Rating for Vicinity Centres (CNRAF)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Penny is a 4-star analyst with an average return of 5.3% and a 66.02% success rate. Penny covers the Real Estate sector, focusing on stocks such as Scentre Group, GPT Group, and Goodman Group.
The word on The Street in general, suggests a Hold analyst consensus rating for Vicinity Centres with a $1.53 average price target.
Based on Vicinity Centres' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $702.3 million and a net profit of $492.6 million. In comparison, last year the company earned a revenue of $642.2 million and had a net profit of $223.5 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
3 Asian Penny Stocks With Market Caps Under US$400M
As global markets react to economic data and potential interest rate changes, Asian markets have shown resilience, with key indices like Japan's Nikkei 225 reaching record highs. Amidst this backdrop, the concept of penny stocks—often seen as a relic from past market eras—remains relevant due to their potential for growth at lower price points. These stocks typically represent smaller or newer companies that can offer significant opportunities when backed by strong financials and sound fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.00 THB3.95B ★★★★★☆ JBM (Healthcare) (SEHK:2161) HK$3.07 HK$2.5B ★★★★★★ Lever Style (SEHK:1346) HK$1.63 HK$1.01B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.65 HK$2.21B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.625 SGD253.31M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.83 SGD11.14B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.64 THB9.37B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.64 SGD998.63M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's explore several standout options from the results in the screener. Hengxin Technology Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hengxin Technology Ltd. is an investment holding company involved in the research, design, manufacture, development, and sale of integrated antennas and feeder cables for mobile communications both in the People's Republic of China and internationally, with a market cap of HK$1.02 billion. Operations: Hengxin Technology generates revenue from three main segments: Telecommunications Business (CN¥2.10 billion), New Energy and Services Business (CN¥185.97 million), and Integrated Circuits and Digital Technology (CN¥238.35 million). Market Cap: HK$1.02B Hengxin Technology Ltd., with a market cap of HK$1.02 billion, operates across telecommunications, new energy, and integrated circuits sectors. Despite negative earnings growth over the past year and declining profits over five years, the company maintains a satisfactory net debt to equity ratio of 25.8% and covers short-term liabilities with assets of CN¥2.9 billion. Recent strategic expansion into green energy infrastructure through an 800MW/1600MWh storage project in Shandong Province marks a significant milestone for future growth potential. However, frequent board changes may indicate instability; recent appointments include experienced financial professionals to strengthen governance. Click to explore a detailed breakdown of our findings in Hengxin Technology's financial health report. Evaluate Hengxin Technology's historical performance by accessing our past performance report. VPower Group International Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: VPower Group International Holdings Limited is an investment holding company that designs, integrates, sells, and installs engine-based electricity generation units across Hong Kong, Mainland China, other Asian countries, Latin America, and internationally with a market cap of approximately HK$1.90 billion. Operations: The company's revenue is primarily derived from its System Integration segment, which generated HK$628.55 million, and its Investment, Building and Operating segment, contributing HK$917.56 million. Market Cap: HK$1.9B VPower Group International Holdings, with a market cap of HK$1.90 billion, is navigating financial challenges as it remains unprofitable with losses increasing over the past five years. However, the company has maintained stable weekly volatility and avoided shareholder dilution recently. Its short-term assets exceed both short and long-term liabilities, providing some financial stability despite a high net debt to equity ratio of 127.2%. Recent corporate guidance indicates an expected profit of approximately HK$20 million for H1 2025 due to asset disposals and reduced interest expenses, contrasting with a significant loss in the previous year. Take a closer look at VPower Group International Holdings' potential here in our financial health report. Learn about VPower Group International Holdings' historical performance here. C-MER Medical Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: C-MER Medical Holdings Limited is an investment holding company that offers ophthalmic services under the C-MER Dennis Lam brand in Hong Kong and Mainland China, with a market cap of HK$2.59 billion. Operations: The company generates revenue from its Hong Kong medical business (HK$901.59 million), Mainland China dental operations (HK$464.58 million), and ophthalmic services in Mainland China (HK$546.99 million). Market Cap: HK$2.59B C-MER Medical Holdings, with a market cap of HK$2.59 billion, faces profitability challenges as losses have grown at 16.5% annually over the past five years. Despite this, the company maintains financial stability with short-term assets exceeding liabilities and cash reserves surpassing total debt. Recent strategic moves include a share buyback program aimed at enhancing net asset value per share and earnings per share, signaling confidence in its long-term prospects. Leadership changes see Dr. Lam transitioning to a senior advisor role while Ms. Li Xiaoting assumes CEO duties, potentially ensuring continuity in corporate strategy and operations. Navigate through the intricacies of C-MER Medical Holdings with our comprehensive balance sheet health report here. Review our historical performance report to gain insights into C-MER Medical Holdings' track record. Make It Happen Get an in-depth perspective on all 970 Asian Penny Stocks by using our screener here. Curious About Other Options? AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1085 SEHK:1608 and SEHK:3309. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
4 hours ago
- Yahoo
Astera Labs Announces Third Quarter 2025 Financial Conference Participation
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in financial conferences for the third quarter 2025. Deutsche Bank 2025 Technology Conference on Aug. 28, 2025. Astera Labs' presentation is scheduled for 12:30 pm PT. Citi's 2025 Global TMT Conference on Sept. 4, 2025. Astera Labs' presentation is scheduled for 8:50 am ET. A webcast of each session will be made available on Astera Labs' investor relations website at About Astera Labs Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions grounded in open standards. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs' Intelligent Connectivity Platform integrates CXL®, Ethernet, PCIe®, and UALink™ semiconductor-based technologies with the company's COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. Discover more at IR CONTACT: Leslie
Business Wire
4 hours ago
- Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3 rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10 th, 2025 Location: New York, NY Format: Fireside chat & 1x1 meetings Time: 8:30 a.m. ET Live webcasts of the fireside chats will be available by visiting the 'Investors & Media' section of the Arcus Biosciences website at Replays will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit
